$ABOS
Acumen Pharmaceuticals, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Newton, MA
ABOS chart
What traders are saying about $ABOS
Latest postsAcumen Pharmaceuticals, Inc. news
- Acumen EBD candidate ACU401 shows 40-fold brain delivery boost
scanx.trade ·
- Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
TradingView ·
- Acumen Pharmaceuticals Terminates K2 HealthVentures Term Loan
TipRanks ·
- Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
fool.com ·
- Which Penny Stock Looks Riskiest: Acumen Pharmaceuticals (NASDAQ:ABOS), Senti Biosciences (NASDAQ:SNTI), Theriva Biologics (NYSEAMERICAN:TOVX), Context Therapeutics (NASDAQ:CNTX) or Hain Celestial (NASDAQ:HAIN)?
kalkine.ca ·
- What Does Tiny Market Value Mean: Theriva Biologics (NYSEAMERICAN:TOVX), 22nd Century Group (NASDAQ:XXII), Acumen Pharmaceuticals (NASDAQ:ABOS), Hain Celestial (NASDAQ:HAIN) and Senti Biosciences (NASDAQ:SNTI)?
kalkine.ca ·
- Can These Penny Stock Gains Last: 22nd Century Group (NASDAQ:XXII), Hain Celestial (NASDAQ:HAIN), Senti Biosciences (NASDAQ:SNTI), Acumen Pharmaceuticals (NASDAQ:ABOS) or Context Therapeutics (NASDAQ:CNTX)?
kalkine.ca ·
- Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development
NeurologyLive ·
- Acumen Pharmaceuticals Share News - Latest Updates, Live News & More
scanx.trade ·
- BC-Most Active Stocks
Yahoo Finance ·
- Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
Yahoo Finance ·
- Acumen Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
app.moby.co ·
Acumen Pharmaceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$121.3M | -$102.3M | -$52.4M | -$42.9M |
| Diluted EPS | $-2.00 | $-1.71 | $-1.08 | $-1.06 |
| Total assets (year end) | $122.8M | $239.0M | $310.1M | $196.6M |
| Cash and equivalents (year end) | $54.0M | $35.6M | $66.9M | $130.1M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Acumen Pharmaceuticals, Inc.
- Ticker
- ABOS (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Newton, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1576885
Frequently asked questions
What exchange is Acumen Pharmaceuticals, Inc. listed on?
Acumen Pharmaceuticals, Inc. trades on the Nasdaq under the ticker symbol ABOS.
What industry is Acumen Pharmaceuticals, Inc. in?
Acumen Pharmaceuticals, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Acumen Pharmaceuticals, Inc. headquartered?
Acumen Pharmaceuticals, Inc.'s business address on file with the SEC is in Newton, MA.
When does Acumen Pharmaceuticals, Inc.'s fiscal year end?
Acumen Pharmaceuticals, Inc.'s fiscal year ends on December 31.